Pfizer is due to release its earnings in the US tonight and the stage is set for what's been dubbed "record-shattering revenues", and analysts believe two new products will bring sales beyond the US$1 billion mark. But can the pharmaceutical giant sustain these gains in the medium to long term? Michelle Martin finds out.

Money and Me: The S-REIT Comeback - Income, Upgrades and What to Buy in 2026
20:16

Market View: Banks Beat, Markets Blink and K-Pop Breaks the Rules
21:24

Money and Me: When Interest Rates are on the Floor, When is Investing Smart Leverage or a Debt Trap?
28:27